WallStreetZenWallStreetZen

NASDAQ: MDGL
Madrigal Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Madrigal Pharmaceuticals earnings were -$325.1M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest MDGL earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$57.9M, down 38.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MDGL reported annual earnings of -$288.3M, with -38.1% growth.

MDGL earnings history

Current Revenue
$1.3B
Current Earnings
-$325.1M
Current Profit Margin
-25.3%

MDGL Return on Equity

Current Company
-56.6%
Current Industry
4.3%
Current Market
39.7%
MDGL's Return on Equity (-56.6%)... subscribe to Premium to read more.
High Return on Equity Performance

MDGL Return on Assets

Current Company
-25.5%
Current Industry
-0.8%
MDGL is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when MDGL announces earnings.

MDGL Return on Capital Employed

Current Company
-33.73%
Current Industry
1.8%
MDGL has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MDGL vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
MDGL-$287.92M-$325.10MN/A-$12.85
SMMT-$855.92M-$856.09MN/A-$0.01
AXSM-$170.94M-$188.30MN/A-$3.72
TECH$255.98M$109.56M-9.99%$0.71
APGE-$268.92M-$274.62MN/A-$4.33
View Top Biotech Stocks

Madrigal Pharmaceuticals Earnings Reports & History FAQ

What were Madrigal Pharmaceuticals's earnings last quarter?

On MDGL's earnings call on Jul 30, 2026, Madrigal Pharmaceuticals (NASDAQ: MDGL) reported Q2 2026 earnings per share (EPS) of -$1.99, up 32.67% year over year. Total MDGL earnings for the quarter were -$57.94 million. In the same quarter last year, Madrigal Pharmaceuticals's earnings per share (EPS) was -$1.50.

If you're new to stock investing, here's how to buy Madrigal Pharmaceuticals stock.

Is Madrigal Pharmaceuticals profitable or losing money?

As of the last Madrigal Pharmaceuticals earnings report, Madrigal Pharmaceuticals is currently losing money. Madrigal Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$325.10 million, a 15.32% increase year over year.

What was MDGL's earnings growth in the past year?

As of Madrigal Pharmaceuticals's earnings date in Jul 30, 2026, Madrigal Pharmaceuticals's earnings has grown year over year. MDGL earnings in the past year totalled -$325.10 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.